Genetic profiling identifies heart attack patients resistant to blood thinners
Results of the GIANT trial reported at TCT 2013 According to a new study, genetic profiling of patients undergoing percutaneous coronary intervention (PCI) may help cardiology teams adjust treatment and improve ischemic outcomes for patients that do not properly metabolize thienopyridine blood thinning therapies such as clopidogrel. Findings from the GIANT trial were presented at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 5, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

Results of the GIANT trial reported at TCT 2013
(Cardiovascular Research Foundation) According to a new study, genetic profiling of patients undergoing percutaneous coronary intervention may help cardiology teams adjust treatment and improve ischemic outcomes for patients that do not properly metabolize thienopyridine blood thinning therapies such as clopidogrel. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 31, 2013 Category: Global & Universal Source Type: news

Massive DAPT Study Sees Early Geographic SignalsMassive DAPT Study Sees Early Geographic Signals
Results for the 26 000-patient trial comparing 12 vs 30 months of aspirin plus clopidogrel or prasugrel are due out in 2014, but early insights are worth keeping an eye on, one investigator says. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 30, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Clopidogrel Plus Aspirin Promising in Stroke PreventionClopidogrel Plus Aspirin Promising in Stroke Prevention
For preventing stroke after TIA, are 2 drugs better than 1? Medscape Neurology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 30, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery Commentary Source Type: news

Clue to unlocking the mystery of life-saving heart drug offered by lung infections
Scientists from the University of Sheffield have discovered ground breaking clues as to how the pioneering heart drug ticagrelor might reduce the risk of dying following a heart attack, in comparison to previous standard treatments. The new findings, published in Platelets, show that ticagrelor may reduce the risk of dying as a result of a lung infection after suffering a heart attack compared to patients treated with the drug clopidogrel... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 16, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

Clopidogrel Contribution to Fracture Risk in Stroke 'Minor'Clopidogrel Contribution to Fracture Risk in Stroke 'Minor'
The increased fracture risk associated with the stroke itself far exceeds that associated with clopidogrel, new research indicates. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 11, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Ticagrelor and Outcomes for Patients With Prior CABGTicagrelor and Outcomes for Patients With Prior CABG
Patients with prior CABG who present with acute coronary syndromes have a high risk for recurrent events. Is intensive antiplatelet therapy with ticagrelor beneficial in this setting -- when compared with clopidogrel? American Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 26, 2013 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Double vs Triple Therapy With PCIDouble vs Triple Therapy With PCI
This F1000 commentary reports on a study comparing clopidogrel therapy with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention. Faculty of 1000 (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 24, 2013 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Two Antiplatelet Add-on Regimens About Equal (CME/CE)
(MedPage Today) -- Adding cilostazol (Pletal) to standard dual antiplatelet therapy performed as well as doubling the dose of clopidogrel (Plavix) after implantation of a drug-eluting stent, the HOST-ASSURE study showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 17, 2013 Category: Cardiology Source Type: news

New pooled analysis shows cangrelor demonstrates reduction in angiographic complications compared to oral clopidogrel
The Medicines Company (NASDAQ: MDCO) reported presentation and publication of a pooled analysis of three Phase III clinical trials of an investigational intravenous (IV) antiplatelet, cangrelor. The trials compared IV cangrelor to either oral clopidogrel or placebo for prevention of thrombotic (clotting) complications during and after percutaneous coronary intervention (PCI). The findings of the pooled CHAMPION program confirm the results of the CHAMPION PHOENIX trial presented and published in April 2013... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 6, 2013 Category: Consumer Health News Tags: Heart Disease Source Type: news

ARCTIC-GENE Strikes Against Genotype-Guided AntiplateletsARCTIC-GENE Strikes Against Genotype-Guided Antiplatelets
It's an inspired idea that isn't panning out, at least based on the genetic substudy of a trial looking at platelet-monitoring-guided therapy in coronary stenting: patients with a slow-clopidogrel-metabolization genotype had poorer clopidogrel responses, but therapy adjustments based on that information didn't help clinically. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 4, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

ARCTIC-GENE throws cold water on genotype-guided antiplatelet therapy at PCI
It's an inspired idea that isn't panning out, at least based on the genetic substudy of a trial looking at platelet-monitoring-guided therapy in coronary stenting: patients with a slow-clopidogrel-metabolization genotype had poorer clopidogrel responses, but therapy adjustments based on that information didn't help clinically. (Source: theHeart.org)
Source: theHeart.org - September 4, 2013 Category: Cardiology Source Type: news

Heparin, grad students, a clinical revolution and giving credit where it's due
The story of a grad student who overcame remarkable odds only to be denied his moment of glory, or a tale of dark deceit and devilish doings? The story of heparin is as complicated as the chemistry itselfBlood is remarkable.A liquid that carries nutrients, waste products and the ever-vigilant cells of the immune system around the body, blood rapidly turns into a solid when it leaves its veins and arteries and becomes exposed to bodily tissues or the air outside. This process of solidification – clotting, or coagulation – is executed and controlled by a complex set of reactions and interactions primarily involvi...
Source: Guardian Unlimited Science - September 4, 2013 Category: Science Authors: Richard P Grant Tags: theguardian.com Blogposts Science Source Type: news

Public Citizen Petitions FDA to Strengthen Plavix WarningsPublic Citizen Petitions FDA to Strengthen Plavix Warnings
The consumer watchdog group wants the agency to revise the warning labeling, distribute an updated patient guide, and ask companies to send "Dear Doctor" letters warning of preventable bleeding adverse effects that occur after one year of clopidogrel use. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 22, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Public Citizen to FDA: No more clopidogrel one year post-DES
The consumer watchdog group wants the agency to revise the warning labeling, distribute an updated patient guide, and ask companies to send "Dear Doctor" letters warning of preventable bleeding adverse effects that occur after one year of clopidogrel use. (Source: theHeart.org)
Source: theHeart.org - August 21, 2013 Category: Cardiology Source Type: news

Personalized drug dosing necessary for older heart patients
Older heart patients present unique challenges for determining the optimal dosages of medications, so a new study from researchers at Duke Medicine offers some rare clarity about the use of drugs that are used to treat patients with heart attacks. For certain heart patients older than age 75, a half-dose of the anti-platelet drug prasugrel works about as well as the typical dosage of clopidogrel, according to a team led by the Duke Clinical Research Institute that looked at a sub-study of a large clinical trial... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 20, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

Baseline Angiography Subgroup Sees Prasugrel Benefit Baseline Angiography Subgroup Sees Prasugrel Benefit
It's not that angiography led to some unprecedented therapeutic benefit, investigators caution; rather, it signaled a group of patients who actually did better on prasugrel than clopidogrel in this otherwise negative trial. Heartwire (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 16, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Baseline angiography subgroup sees prasugrel benefit in TRILOGY ACS
It's not that angiography led to some unprecedented therapeutic benefit, investigators caution; rather, it signaled a group of patients who actually did better on prasugrel than clopidogrel in this otherwise negative trial. (Source: theHeart.org)
Source: theHeart.org - August 16, 2013 Category: Cardiology Source Type: news

TRILOGY ACS: Prasugrel 5 mg vs Clopidogrel in ElderlyTRILOGY ACS: Prasugrel 5 mg vs Clopidogrel in Elderly
Cutting its dosage in half for patients aged 75 or older lowered prasugrel's bleeding risk to clopidogrel's risk level while providing comparable clinical benefit in the TRILOGY ACS trial; concerns were that a full prasugrel dosage in the elderly would pose too much of a bleeding risk. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 30, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

High platelet reactivity on clopidogrel predicts stent thrombosis, heart attack, and bleeding
Patients who receive a drug-eluting stent (DES) and demonstrate high platelet reactivity on clopidogrel are more likely to have blood clots form on the stent and to suffer a heart attack; however, these patients are less likely to develop bleeding complications. One-year results of the ADAPT-DES trial was published online in The Lancet. The findings were first presented at last year's Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 30, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

Prasugrel 5 mg, clopidogrel similarly safe, effective in non-PCI elderly with ACS
Cutting its dosage in half for patients aged>75 lowered prasugrel's bleeding risk to clopidogrel's risk level while providing comparable clinical benefit in the TRILOGY ACS trial; concerns were that a full prasugrel dosage in the elderly would pose too much of a bleeding risk. (Source: theHeart.org)
Source: theHeart.org - July 29, 2013 Category: Cardiology Source Type: news

1-year results of ADAPT-DES trial published in The Lancet
(Cardiovascular Research Foundation) Patients who receive a drug-eluting stent and demonstrate high platelet reactivity on clopidogrel are more likely to have blood clots form on the stent and to suffer a heart attack; however, these patients are less likely to develop bleeding complications. One-year results of the ADAPT-DES trial will be published online July 26, 2013, in The Lancet. The findings were first presented at last year's Transcatheter Cardiovascular Therapeutics annual scientific symposium. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 26, 2013 Category: Global & Universal Source Type: news

Clopidogrel in Infants with Systemic-to-Pulmonary-Artery Shunts
Medications approved for adults often have additional uses in pediatric patients. Such is the case -- as described by Wessel and colleagues -- for clopidogrel, an agent that blocks the P2Y12 component of adenosine diphosphate (ADP) receptors on the surface of platelets. ADP receptors prevent the activation of the glycoprotein IIb/IIIa receptor complex, thereby reducing aggregation. Clopidogrel is used most commonly as a prophylactic antiplatelet therapy in adults with atherosclerotic cardiovascular disease, but is increasingly employed in the pediatric population, particularly in those with cardiac disease. Pediatric cardi...
Source: SCCM RSS News - July 8, 2013 Category: Intensive Care Source Type: news

Risk Of Stroke Effectively Reduced By Simple 2-Drug Combination
Results of a Phase III clinical trial showed that a simple drug regimen of two anti-clotting drugs - clopidogrel and aspirin- lowered the risk of stroke by almost one-third, compared to the standard therapy of aspirin alone, when given to patients who had minor or transient stroke symptoms to prevent subsequent attacks. Described this week in the New England Journal of Medicine (July 4, 2013 print issue), the clinical trial was conducted at multiple sites in China and designed in partnership with a physician at UC San Francisco... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 28, 2013 Category: Consumer Health News Tags: Stroke Source Type: news

Drug Combo Cuts Stroke Risk After TIA
A simple combination of two anti-clotting drugs, clopidogrel and aspirin, can cut the risk of a stroke in patients who have already experienced a mini-stroke or transient ischemic attack (TIA). This was the result of a phase 3 clinical trial conducted in China with the help of a US physician who says it could change the standard of care in the US. The investigators report their findings in the 26 June online issue of the New England Journal of Medicine, NEJM. The trial took place at several sites in China and was designed in partnership with S... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 27, 2013 Category: Consumer Health News Tags: Stroke Source Type: news

After Minor Stroke, Adding Clopidogrel to Aspirin Reduces Further Risk in Some (FREE)
By Joe Elia Patients taking clopidogrel in addition to aspirin after minor ischemic stroke show a lower risk for early recurrence, according to a New England Journal of Medicine study. An … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 27, 2013 Category: Primary Care Source Type: news

Drug Combo May Reduce Risk of Second Stroke: Study
After small or mini-stroke, aspirin plus Plavix tied to lower odds of another event (Source: WebMD Health)
Source: WebMD Health - June 27, 2013 Category: Consumer Health News Source Type: news

Drug Combo May Reduce Risk of Second Stroke
After small or mini-stroke, aspirin plus Plavix tied to lower odds of another event Source: HealthDay Related MedlinePlus Pages: Blood Thinners, Stroke (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - June 26, 2013 Category: Consumer Health News Source Type: news

International study on fragile newborns challenges current practices
(Children's National Medical Center) One of the largest clinical trials done in infants with congenital heart diseases, published in the New England Journal of Medicine, shows that the increasingly common practice of using the drug clopidogrel (Plavix) to reduce shunt-related blood flow issues is not effective in the dose studied. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 20, 2013 Category: Global & Universal Source Type: news

Plavix No Help in Kids' Cyanotic Heart Disease (CME/CE)
(MedPage Today) -- Children with cyanotic congenital heart disease derived no benefit from prophylactic clopidogrel for shunt thrombosis, a large, randomized trial showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 20, 2013 Category: Cardiology Source Type: news

Risk of unfavorable long-term outcome in older adults with traumatic intracranial hemorrhage and anticoagulant or antiplatelet use - Nishijima DK, Shahlaie K, Sarkar K, Rudisill N, Holmes JF.
The objective was to compare neurological outcomes at 6 months in older patients with preinjury warfarin or clopidogrel use and mild traumatic intracranial hemorrhage with those without prior use of these medications. METHODS: This was a r... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - June 17, 2013 Category: Global & Universal Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

No Aspirin With Anticoag/Clopidogrel After MI, PCI in AFNo Aspirin With Anticoag/Clopidogrel After MI, PCI in AF
A large national cohort study somewhat confirms what the WOEST trial suggested: that an oral anticoagulant plus one antiplatelet is sufficient in patients with multiple indications for antithrombotic therapy. Heartwire (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 7, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Aspirin unneeded with anticoagulation/clopidogrel after MI, PCI in AF
A large national cohort study somewhat confirms what the WOEST trial suggested: that an oral anticoagulant plus one antiplatelet is sufficient in patients with multiple indications for antithrombotic therapy. (Source: theHeart.org)
Source: theHeart.org - June 6, 2013 Category: Cardiology Source Type: news

Concomitant Use of Clopidogrel and Proton-Pump InhibitorConcomitant Use of Clopidogrel and Proton-Pump Inhibitor
PPI's may inhibit more than just proton pumping. Find out the latest on how they compete with clopidogrel. Interventional Cardiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 31, 2013 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Post-polypectomy Bleeding in Patients on ClopidogrelPost-polypectomy Bleeding in Patients on Clopidogrel
Are patients taking clopidogrel undergoing polypectomy at a greater risk for bleeding after the procedure and, if so, how could it be prevented? Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 14, 2013 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

French competition body fines Sanofi in Plavix dispute
PARIS (Reuters) - The French Competition Authority said on Tuesday it fined drugmaker Sanofi 40.6 million euros ($52.7 million) over what it called a smear campaign aimed at stifling generic competition to its blood thinner, Plavix. (Source: Reuters: Health)
Source: Reuters: Health - May 14, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Genes a Part of PPI-Clopidogrel Interaction (CME/CE)
ORLANDO (MedPage Today) -- Among patients who have had an MI and who have a genotype associated with ultra-rapid metabolism of clopidogrel, use of proton pump inhibitors may worsen outcomes, a study found. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 14, 2013 Category: Cardiology Source Type: news

U.S. spending on medicines fell for first time in 2012
(Reuters) - Patent expirations on big-name drugs such as Lipitor and Plavix has resulted in modestly less spending on medicines in the United States for the first time in at least 55 years, according to a report released on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - May 9, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Clopidogrel Boosts Bleeding Risk After PolypectomyClopidogrel Boosts Bleeding Risk After Polypectomy
Patients on clopidogrel have a higher than average risk for bleeding when they have polyps removed during colonoscopy, pooled data suggest. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 10, 2013 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

STREAM Trial Data Supports An Early Fibrinolysis-Based Strategy For Patients With STEMI Who Cannot Undergo Primary PCI
New data published in NEJM demonstrates that patients with STEMI who cannot undergo primary PCI within 60 minutes of first medical contact have similar clinical outcomes with early fibrinolysis with Metalyse® (tenecteplase, TNK-tPA) in combination with clopidogrel and enoxaparin, followed by timely angiography (pharmaco-invasive strategy), compared to patients given primary PCI after the 60-minute window.(1) "In STEMI patients, the most important thing is to re-establish blood supply to the heart... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 25, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

CHMP adopts new indication for new strength of rivaroxaban (Xarelto®)
Source: European Medicines Agency Area: News The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a variation to the terms of the marketing authorisation for rivaroxaban (Xarelto®).    The CHMP has adopted a new indication for a new strength 2.5mg as follows: "Xarelto, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers."   Detailed ...
Source: NeLM - Cardiovascular Medicine - March 25, 2013 Category: Cardiology Source Type: news

NEJM Paper Confirms Value Of Early Fibrinolysis In STEMI
New England Journal of Medicine (NEJM) paper shows prehospital or early fibrinolysis with Metalyse® (tenecteplase) delivers comparable clinical outcomes to gold standard intervention for patients who would not have access to primary PCI within 60 minutes after the first medical contact(b) New data published in NEJM demonstrates that patients with STEMI who cannot undergo primary PCI within 60 minutes of first medical contact have similar clinical outcomes with early fibrinolysis with Metalyse® (tenecteplase, TNK-tPA) in combination with clopidogrel and enoxaparin... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 22, 2013 Category: Consumer Health News Tags: Heart Disease Source Type: news

Bleeds in Triple Therapy May Hinge on Drug Choice (CME/CE)
(MedPage Today) -- Substituting prasugrel (Effient) for clopidogrel (Plavix) in stented patients on triple therapy may increase the risk of bleeding, researchers found. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 21, 2013 Category: Cardiology Source Type: news

ACC: Extra-Long Plavix Course No Help After Stenting (CME/CE)
SAN FRANCISCO (MedPage Today) -- Extra-extended dual antiplatelet therapy after placement of a drug-eluting stent won't boost outcomes, Korean researchers affirmed in the DES-LATE trial. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 16, 2013 Category: Cardiology Source Type: news

Clopidogrel/atorvastatin protect in carotid stenting
A 600-mg clopidogrel load and a short-term reload with high-dose atorvastatin provided neuroprotection in patients undergoing carotid stenting. (Source: theHeart.org)
Source: theHeart.org - March 14, 2013 Category: Cardiology Source Type: news

Clot Buster Safe for Stroke Patients on Blood Thinners
Fears that giving tPA to those taking aspirin or Plavix might raise risk of brain bleeds largely unfounded, researchers say Source: HealthDay Related MedlinePlus Pages: Blood Thinners, Stroke (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - March 14, 2013 Category: Consumer Health News Source Type: news

Clopidogrel/Atorvastatin Protect in Carotid StentingClopidogrel/Atorvastatin Protect in Carotid Stenting
A 600-mg clopidogrel load and a short-term reload with high-dose atorvastatin provided neuroprotection in patients undergoing carotid stenting. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 14, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

ACC: Statin Plus Plavix Aids in Carotid Stenting (CME/CE)
SAN FRANCISCO (MedPage Today) -- A higher loading dose of clopidogrel (Plavix) along with a reload of atorvastatin (Lipitor) was neuroprotective in patients having carotid stenting, researchers reported here. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 14, 2013 Category: Cardiology Source Type: news

No Stent Thrombosis Seen When Plavix and Aspirin Stopped Early
Important news for stent patients and cardiologists alike: data from a new analysis of Medtronic's (NYSE: MDT) RESOLUTE drug-eluting stent program show very low occurrence of stent thrombosis when dual antiplatelet therapy (DAPT) is interrupted or discontinued after one month. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - March 14, 2013 Category: Cardiology Source Type: news

Cangrelor, New Anti-Clotting Drug More Effective Than Current Treatment
A new and experimental anti-clotting drug, cangrelor, proved better than the commonly used clopidogrel and was significantly more effective at preventing blood clots in a large trial of patients who underwent coronary stent procedures. These data, from the phase III CHAMPION PHOENIX study, were presented at the American College of Cardiology's 62nd Annual Scientific Session and published simultaneously in the New England Journal of Medicine. Researchers report that the new drug, which is administered intravenously, reduced the odds of complications from stenting procedures... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 13, 2013 Category: Consumer Health News Tags: Blood / Hematology Source Type: news